Metabolic Bariatric Surgery Leads to Similar Benefits for Diabetes Management and Glycaemia in Remitters and Non‐Remitters
Authors' conclusion
While those who do not experience post-MBS remission have a longer diabetes duration and higher baseline adjusted HbA1c, they benefit similarly from improvements in glycaemia and de-escalation of treatment as those who remit. We suggest that the likelihood of diabetes remission, as assessed by scoring systems, should not be used as a criterion to recommend MBS to patients.
Study context
- Population
- Adults with obesity and Type 2 diabetes undergoing a standardised RYGB in the United Kingdom or Singapore; multiethnic cohortdiscovery cohort 67 · validation cohort (separate UK cohort undergoing RYGB) 195
- Exposure
- Remitters vs non-remitters
- Outcome
- Diabetes remission
- Follow-up
- 12-15 months
Methodological detailsdiscovery cohort, validated by retrospective clinical audit of a separate UK cohort
- Discovery cohort
- Validated by retrospective clinical audit of a separate UK cohort
Main finding
As reported in the abstract
- Diabetes remission was predicted by diabetes duration, measures of treatment intensity and resulting glycaemia (expressed as adjusted HbA1c) and post-prandial insulin secretion
Observational data: associations, not effects.
Further findings
| Outcome | REMITTERS | NON-REMITTERS | P value |
|---|---|---|---|
| Change in adjusted HbA1c (discovery cohort)Similar improvements | −38.2 ± 17.5 mmol/mol | −39.5 ± 15.5 mmol/mol | P = 0.739 |
Change in adjusted HbA1c (discovery cohort)
- Finding confirmed in the validation cohort
Original publication
Metabolic Bariatric Surgery Leads to Similar Benefits for Diabetes Management and Glycaemia in Remitters and Non‐Remitters. Diabetes Obes Metab. Published 10 November 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →